Baird analyst David Rescott raised the firm’s price target on iRhythm (IRTC) to $220 from $180 and keeps an Outperform rating on the shares. The firm updated its model afterlaying out its bull caseon 2027 estimates. The shares remain a top small-midcap idea.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on IRTC:
- iRhythm price target raised to $205 from $183 at Citi
- iRhythm price target raised to $193 from $170 at Canaccord
- CoreWeave upgraded, Lululemon downgraded: Wall Street’s top analyst calls
- iRhythm initiated with an In Line at Evercore ISI
- Irhythm Technologies: Strategic Market Expansion and Clinical Efficacy Drive Buy Rating